Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

SYNH Vs. NXGN: Which Stock Should Value Investors Buy Now?

Published 09/29/2019, 09:30 PM
Updated 07/09/2023, 06:31 AM

Investors looking for stocks in the Medical Info Systems sector might want to consider either Syneos Health (SYNH) or Nextgen Healthcare (NXGN). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.

There are plenty of strategies for discovering value stocks, but we have found that pairing a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system produces the best returns. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our Style Scores work to grade companies based on specific traits.

Syneos Health has a Zacks Rank of #2 (Buy), while Nextgen Healthcare has a Zacks Rank of #3 (Hold) right now. Investors should feel comfortable knowing that SYNH likely has seen a stronger improvement to its earnings outlook than NXGN has recently. But this is only part of the picture for value investors.

Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels.

Our Value category highlights undervalued companies by looking at a variety of key metrics, including the popular P/E ratio, as well as the P/S ratio, earnings yield, cash flow per share, and a variety of other fundamentals that have been used by value investors for years.

SYNH currently has a forward P/E ratio of 16.73, while NXGN has a forward P/E of 18. We also note that SYNH has a PEG ratio of 1.59. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. NXGN currently has a PEG ratio of 3.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Another notable valuation metric for SYNH is its P/B ratio of 1.95. The P/B is a method of comparing a stock's market value to its book value, which is defined as total assets minus total liabilities. By comparison, NXGN has a P/B of 2.63.

These metrics, and several others, help SYNH earn a Value grade of A, while NXGN has been given a Value grade of C.

SYNH has seen stronger estimate revision activity and sports more attractive valuation metrics than NXGN, so it seems like value investors will conclude that SYNH is the superior option right now.



Syneos Health, Inc. (SYNH): Free Stock Analysis Report

NEXTGEN HEALTHCARE, INC (NXGN): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.